Aviceda Therapeutics

Edit info

Founded: 2018

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin2/Clin3

Therapy area: Geographic atrophy

Drug types: OPH, HEP, LNG, NEU, NEU

Lead product: AVD-104

Funding: <10M

avicedarx.com

linkedin.com

job board

Drug notes:

Also Clin0 DME, Clin0 other eye conditions; 4 undisclosed programs RD/Clin0 IPF, liver fibrosis, myelofibrosis, lung inflammation, neurodegeneration, neuroinflammation, solid tumors

About:

Aviceda Therapeutics is developing glyco-therapeutics that modulate immune system dysfunction. The human glycome is far more diverse than the proteome or genome and plays a role in regulating innate immune checkpoints. Aviceda is using their technology platform to engineer highly optimized glyco-ligands that can modulate the self-recognition receptors on immune cells and convert them to a resolution state. Aviceda’s lead candidate, AVD-103, is being developed to target various immune system responses that contribute to pathology associated with dry age-related macular degeneration. AVD-104 is one of several glyco-immune therapeutics Aviceda is developing that are delivered via biodegradable nanoparticles.